Will you offer adjuvant olaparib to patients with somatic BRCA mutated breast cancer given that OlympiA only enrolled germline BRCA+?

I agree that the 3-year DFS benefit is quite compelling for considering adjuvant olaparib in patients meeting the eligibility criteria in NSABP B55 (Tutt et al., PMID 34081848). This also raises the possibility of clinical benefit in other scenarios, particularly those where PARPi have shown meaning...

We know that there are responses to PARPi in patients who have somatic BRCA mutations both from the experience in ovarian cancer and in a small breast cancer experience in TBCRC 048. There are challenges in the metastatic setting because it is not clear in some cases whether the somatic alteration i...